ClinicalTrials.gg
RecruitingNCT07566195ROMEOUpdated Oct 16, 2026

Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations

A Phase 3 interventional study of Tozorakimab Dose Regimen 1 and Tozorakimab Dose Regimen 2 in Chronic Obstructive Pulmonary Disease and COPD, sponsored by AstraZeneca. Recruiting at 13 sites in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Planned enrollment
132nd of 194
59 · median 137
Started
2026
with 2 others
Phase 3
76 of 284
4 open now
Primary completion
2028-12
later than 12 of 14 live
Registered
283rd of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 132nd largest by planned enrollment of the 194 interventional ones that give a count, is one of 3 that started in 2026, is one of 76 in phase 3, reaches primary completion later than 12 of the 14 other live ones, and was the 283rd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations.

Eligible participants must have completed one of the predecessor studies.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • COPD

Keywords

  • Tozorakimab
  • MEDI3506
  • Chronic Obstructive Pulmonary Disease
  • COPD
  • Exacerbations
  • Safety
  • Biologic
  • Biologic Treatment
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants previously randomized in predecessor studies.
  2. Participants should be affiliated with the French Social Security system.
  3. Participants who are willing to continue using methods as agreed to for the predecessor studies.
  4. Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  1. pulmonary disease other than .
  2. Participant meeting criteria for IP discontinuation as judged by the Investigator or the Sponsor.
  3. Current alcohol, drug or chemical abuse.
  4. Treatment with systemic or other medication within 2 weeks prior to Visit 1 of ROMEO.
  5. Known history of:

    1. Severe allergic reaction to any monoclonal and polyclonal antibody.
    2. Allergy or reaction to any component of the IMP formulation.
  6. Receipt of blood products or immunoglobulins within 30 days prior to visit 1 of ROMEO.
  7. Receipt of within 30 days prior to visit 1 of ROMEO.
  8. Chronic use (or expected need for chronic use during the study) of immunosuppressive medications (including, but not limited to, systemic corticosteroids), marketed or biologic, or another prohibited medication.
  9. Chronic use of antibiotics if the duration of treatment is \< 3 months prior to Visit 1 of ROMEO (first IMP administration). Chronic macrolide or other antibiotic therapy is allowed provided the participant has been on a stable dose/regimen for ≥ 3 months prior to Visit 1 of ROMEO (first IMP administration) and has had at least one COPD exacerbation while on stable therapy.
  10. Use of allergen immunotherapy within 3 months of Visit 1 of ROMEO (first IMP administration), except for stable maintenance dose allergen-specific immunotherapy started 4 weeks prior to V1.
  11. Use of interferon gamma within 3 months of visit 1 of ROMEO (first IMP administration).
  12. Participation in any interventional clinical trial or receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to Visit 1 of ROMEO (first IMP administration), whichever is longer.
  13. Involvement in the planning and/or conduct of the study (applies to both staff employed by the Sponsor and/or staff at the study site).
  14. Participants who are not able to comply with the study requirements, procedures, and restrictions.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (estimated)

Study arms

  • Experimental
    Tozorakimab Dose Regimen 1

    Subcutaneous injection of Tozorakimab via a pre-filled syringe.

    Drug: Tozorakimab Dose Regimen 1

  • Experimental
    Tozorakimab Dose Regimen 2

    Subcutaneous injection of Tozorakimab via a pre-filled syringe.

    Drug: Tozorakimab Dose Regimen 2

Interventions

  • DrugTozorakimab Dose Regimen 1

    Participants previously randomised in the MIRANDA predecessor study will receive Tozorakimab in ROMEO according to this dose regimen

  • DrugTozorakimab Dose Regimen 2

    Participants previously randomised in the TITANIA or PROSPERO predecessor studies will receive Tozorakimab in ROMEO according to this dose regimen

06

What researchers measure

Primary outcomes

  1. Adverse events

    Assessments related to AEs include: Occurrence/frequency, Relationship to IMP as assessed by Investigator, Intensity, Seriousness, Death, AEs leading to discontinuation of IMP, Other significant AEs. Medically significant abnormal laboratory results will be reported as AEs.

    Time frame: 2-3 years

07

Study locations

5 of 13 sites recruiting
  • Research Site
    Aix-en-Provence, 13616, France
    Active, not recruiting

    Not enrolling at this site.

  • Research Site
    Brest, 29609, France
    Active, not recruiting

    Not enrolling at this site.

  • Research Site
    Colmar, 68024, France
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Gleizé, 69400, France
    Active, not recruiting

    Not enrolling at this site.

  • Research Site
    Grenoble, 38043, France
    Recruiting
  • Research Site
    Lyon, 69317, France
    Recruiting
  • Research Site
    Marseille, 13015, France
    Recruiting
  • Research Site
    Montpellier, 34295, France
    Recruiting
  • Research Site
    Pessac, 33600, France
    Recruiting
  • Research Site
    Pringy, 74374, France
    Active, not recruiting

    Not enrolling at this site.

  • Research Site
    Quimper, 29000, France
    Active, not recruiting

    Not enrolling at this site.

  • Research Site
    Saint-Herblain, 44800, France
    Active, not recruiting

    Not enrolling at this site.

  • Research Site
    Toulouse, 31000, France
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at : https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2028, 31 months after the start.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 31 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 4, 2026
StartActual
May 5, 2026
Primary completionEst.
Dec 29, 2028
CompletionEst.
Dec 29, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07566195
Lead sponsor
AstraZeneca
Collaborators
Clinact, Multihealth Group, Contract Research Organization
Responsible party
Sponsor
First posted
May 4, 2026
Start date
May 5, 2026
Primary completion
Dec 29, 2028 (estimated)
Completion
Dec 29, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion